NCT06661694

A Study to Learn How Different Tablets of the Study Medicine Mevrometostat Are Taken up Into the Blood in Healthy Adults

A PHASE 1, RANDOMIZED, OPEN-LABEL, 4-PERIOD, CROSSOVER, SINGLE-DOSE STUDY IN HEALTHY PARTICIPANTS TO ESTIMATE THE EFFECT OF TABLET FORMULATION ON THE RELATIVE BIOAVAILABILITY OF MEVROMETOSTAT (PF-06821497)

• Status: Withdrawn
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 0 (actual)
• Sponsor: Pfizer · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Accepted

Summary

The purpose of the study is to compare the amount of mevrometostat available from four different tablet formulations, taken with food, in healthy adult participants. This study is seeking male or female participants who: * are 18 years or older * are healthy as decided by medical tests. * have a Body mass index (BMI) of 16 to 32 kilogram per meter squared * a total body weight of more than 50 kilograms (110 pounds). All participants will take part in 4 study periods to receive 4 different treatments, which are assigned in a random order. There will also be a 5-day gap between each study period. This is done so that the medicine is passed out of the body before the start of the next period. Each treatment consists of a single dose of mevrometostat (PF-06821497), and the treatments differ only by tablet formulation. How the medicine is processed in the body will be studied after giving the medicines to the participants. This will be done by collecting blood samples after giving each of these tablets. The results will be used to see the effect of tablet formulation on the amount of mevrometostat (PF-06821497) available in the blood of the participants. Participants will be in the study for about 12 weeks.

Conditions

• Healthy

Interventions

Type	Name	Description
DRUG	Treatment A	Single 875 mg dose of mevrometostat standard tablet formulation
DRUG	Treatment B	Single 875 mg dose of mevrometostat alternative tablet formulation
DRUG	Treatment C	Single 875 mg dose of mevrometostat alternative tablet formulation
DRUG	Treatment D	Single 875 mg dose of mevrometostat alternative tablet formulation

Timeline

• Start date: 2025-04-28
• Primary completion: 2025-09-08
• Completion: 2025-09-09
• First posted: 2024-10-28
• Last updated: 2025-04-24

Locations

1 site across 1 country: Belgium